Company intelligence / Profile preview
Guangdong Kongming Biotech
Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangdong Kongming Biotech is developing allogeneic γδ T cell therapies for liver cancer, with its main program having reached IND approval as of January 2025; one early clinical trial was initiated for advanced hepatocellular carcinoma, but has been withdrawn.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangdong Kongming Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong Kongming Biotech.